AG 494 - CAS 139087-53-9
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
AG 494
Catalog Number:
139087-53-9
Synonyms:
alpha-Cyano-(3,4-dihydroxy)-N-phenylcinnamide; Tyrphostin AG-494; Tyrphostin B48
CAS Number:
139087-53-9
Description:
AG-494 is a EGFR (epidermal growth factor receptor) kinase inhibitor with IC50 value of 0.7 μM. It is selective over ErbB2, PDGFR and insulin receptor kinase (IC50 values are 42, 6 and > 100 μM respectively). AG-494 tyrphostin also can block Cdk2 activation.
Molecular Weight:
280.28
Molecular Formula:
C16H12N2O3
Quantity:
Milligrams-Grams
Quality Standard:
In-house standard
COA:
Inquire
MSDS:
Inquire
Canonical SMILES:
C(\C(=C\c1cc(c(cc1)O)O)C#N)(=O)Nc1ccccc1
InChI:
1S/C16H12N2O3/c17-10-12(8-11-6-7-14(19)15(20)9-11)16(21)18-13-4-2-1-3-5-13/h1-9,19-20H,(H,18,21)/b12-8+
InChIKey:
HKHOVJYOELRGMV-XYOKQWHBSA-N
Targets:
EGFR
Chemical Structure
CAS 139087-53-9 AG 494

Related EGFR Products


CAS 133550-41-1 AG 556

AG 556
(CAS: 133550-41-1)

AG 556, a dihydroxyphen derivative, has been found to be a EGFR kinase inhibitor that could probably be effective in the study of myocardial infarct and hemodyn...

SKLB-1028
(CAS: 1350544-93-2)

SKLB1028 is a novel Bcr-abl tyrosine kinase inhibitor, Epidermal growth factor inhibitor and Fms-like tyrosine kinase 3 inhibitor originated by CSPC Ouyi Pharma...

CAS 937265-83-3 ARRY-380

ARRY-380
(CAS: 937265-83-3)

ARRY-380 is a potent and selective HER2 inhibitor with IC50 of 8 nM, equipotent against truncated p95-HER2, 500-fold more selective for HER2 versus EGFR.

CAS 1214265-56-1 WZ-3146

WZ-3146
(CAS: 1214265-56-1)

WZ-3146 is an irreversiblely inhibitor against EGFR T790M with potential anticancer activity.

CAS 871026-44-7 TAK-285

TAK-285
(CAS: 871026-44-7)

TAK-285 is a novel dual erbB protein kinase inhibitor that specifically targets human epidermal growth factor receptor (EGFR) and HER2. Methods: TAK-285 is curr...

CAS 487-52-5 Butein

Butein
(CAS: 487-52-5)

Butein, a plant polyphenol isolated from Rhus verniciflua, is able to inhibit the activation of protein tyrosine kinase, NF-κB and STAT3, also inhibits EGFR. Th...

CAS 1214265-57-2 WZ-8040

WZ-8040
(CAS: 1214265-57-2)

WZ8040 is a novel mutant-selective irreversible EGFRT790M inhibitor with potential anticancer activity. WZ8040 is about 30-fold more potent against EGFR T790M, ...

CAS 1050500-29-2 AST-1306

AST-1306
(CAS: 1050500-29-2)

AST-1306 is a novel irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, also effective in mutation EGFR T790M/L858R, more potent to ErbB2-ove...

CAS 937263-43-9 Irbinitinib

Irbinitinib
(CAS: 937263-43-9)

Irbinitinib,also known as ARRY-380 and ONT-380, is an orally bioavailable inhibitor of the human epidermal growth factor receptor tyrosine kinase ErbB-2 (also...

CAS 153436-53-4 AG-1478

AG-1478
(CAS: 153436-53-4)

AG-1478 (NSC 693255) is a selective EGFR inhibitor with IC50 of 3 nM; almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR.

CAS 845272-21-1 Varlitinib

Varlitinib
(CAS: 845272-21-1)

Varlitinib, also known as ARRY-543, is an orally bioavailable inhibitor of the epidermal growth factor receptor family with potential antineoplastic activity. V...

CAS 781613-23-8 XL-647

XL-647
(CAS: 781613-23-8)

XL647 is an orally bioavailable small-molecule receptor tyrosine kinase inhibitor with potential antineoplastic activity. It inhibits EGFR, HER2, VEGFR and EphB...

CAS 118409-57-7 AG-18

AG-18
(CAS: 118409-57-7)

AG 18 (10 μM) inhibits EGF-induced proliferation of GH3 cells.

CAS 1421373-65-0 AZD-9291

AZD-9291
(CAS: 1421373-65-0)

AZD-9291 is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become ...

CAS 383432-38-0 CP-724714

CP-724714
(CAS: 383432-38-0)

CP-724714 is An orally bioavailable quinazoline with potential antineoplastic activity. CP-724,714 selectively binds to the intracellular domain of HER2, revers...

Selatinib
(CAS: 1275595-86-2)

Selatinib is a Epidermal growth factor receptor(EGFR) and ERbB-2 receptor antagonist as an analog of the quinazoline lapatinib with potential antineoplastic act...

CAS 171179-06-9 PD158780

PD158780
(CAS: 171179-06-9)

PD158780 is a potent, cell-permeable, reversible ATP-competitive inhibitor of EGFR tyrosine kinase activity with IC50 values of 0.008, 49 and 52 nM for EGFR, Er...

Transtinib
(CAS: 1246089-27-9)

This active molecular is an irreversible EGFR ( epidermal growth factor receptor ) tyrosine kinase inhibitor. Transtinib shows good anti-proliferative activity ...

CAS 859853-30-8 BMS-6690514

BMS-6690514
(CAS: 859853-30-8)

BMS-690514 is a potent inhibitor of human epidermal growth factor receptor (HER) 1 (EGFR), 2, and 4, and vascular endothelial growth factor receptors (VEGFR) 1-...

CAS 257933-82-7 Pelitinib

Pelitinib
(CAS: 257933-82-7)

Pelitinib is a 3-cyanoquinoline pan-ErbB tyrosine kinase inhibitor with potential antineoplastic activity. EKB-569 irreversibly binds covalently to epidermal gr...

Reference Reading


1.The inhibitory mechanisms of the tyrosine kinase inhibitors herbimycin a, genistein, and tyrphostin B48 with regard to the function of the aryl hydrocarbon receptor in Caco-2 cells.
Kasai S1, Kikuchi H. Biosci Biotechnol Biochem. 2010;74(1):36-43. Epub 2010 Jan 7.
The aryl hydrocarbon receptor (AhR) is a transcription factor that is activated by dioxin and related xenobiotics. Although the activation of AhR is inhibited by tyrosine kinase inhibitors, the molecular mechanism has not been clarified. In the current study, the inhibitory mechanisms of several inhibitors of tyrosine kinase, herbimycin A, genistein, and tyrphostin B48, on AhR activation was analyzed in human Caco-2 cells. All the inhibitors suppressed the transcriptional activation of AhR induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Herbimycin A induced down-regulation of the AhR protein by inhibiting its molecular chaperone heat shock protein 90 (HSP90). In contrast, genistein and tyrphostin B48 inhibited the nuclear localization of AhR induced by TCDD, although the amount of AhR protein was not altered. The inhibitory effects of genistein and tyrphostin B48 on endogenous tyrosine kinase activity were evaluated by detection of alterations in the tyrosine phosphorylation states of cellular proteins.
2.Tyrphostin AG 494 blocks Cdk2 activation.
Osherov N1, Levitzki A. FEBS Lett. 1997 Jun 30;410(2-3):187-90.
We have previously shown that the EGFR kinase selective tyrphostin AG 494 fails to inhibit EGFR kinase in intact cells. Yet, AG 494 proved to inhibit EGF- or serum-induced cell proliferation (Osherov et al., J. Biol. Chem. 268 (1993) 11134-11142). In this preliminary communication we show that AG 494 as well as its close analogs AG 490 and AG 555 block Cdk2 activation. In contrast, AG 1478, a more selective EGFR kinase blocker which is also active as EGFR kinase blocker in intact cells, fails to do so. AG 494 exerts its full inhibitory activity on Cdk2 activation even when added 20 h subsequent to EGF addition when Cdk2 activation is maximal. The inhibitory activity on Cdk2 activation parallels its DNA synthesis inhibitory activity, strongly suggesting that its target is one of the molecular mechanisms involved in Cdk2 activation. AG 494 and its analogs may become useful lead compounds for the development of drugs aimed at the cell cycle machinery.